胃泌素释放肽前体在小细胞肺癌诊断中的临床研究  

A Clinical Study of Serum Progastrin Releasing Peptide in Patients with Small Cell Lung Cancer

作　　者：余文聘[1] 王文莉[1] 黄杰雄[1] 江艺[2] 洪文郁[1] 侯少芝[1] 陈潮钦[1] 吴洁文[1] 

机构地区：[1]汕头大学医学院第一附属医院,广东汕头515041 [2]汕头大学医学院肿瘤医院内科,广东汕头515041

出　　处：《河北医学》2006年第8期703-704,共2页Hebei Medicine

基　　金：汕头市重点科技计划项目汕府科[2003]119号

摘　　要：目的:探讨胃泌素释放肽前体(ProGRP)在小细胞肺癌(SCLC)的临床意义。方法:应用酶联免疫检测(ELISA)法检测21例SCLC、25例非小细胞肺癌(NSCLC)、14例肺良性疾病、12例正常健康者和8例治疗后SCLC患者血清ProGRP。观察其敏感性、特异性和与肿瘤治疗效果的关系。结果:SCLC血清ProGRP值显著高于对照组(P<0.01),以40ng/L为阈值,诊断SCLC的敏感性为76%(16/21),特异性为95%(56/59);临床治疗有效的SCLC患者,治疗后ProGRP水平较治疗前明显下降。结论:ProGRP作为SCLC新的肿瘤标志物,具有敏感性高、特异性强的特点,并可准确反映SCLC对化疗的反应。Objective： To explore the serum progastrin releasing peptide in patients with small cell lung cancer（ SCLC ）. Method： Serum level of ProGRl：r31 -98 was measured by ELISA in 21 patients with SCLC, 25 patients with non - small cell lung cancer（ NSCLC ）, 8 patients with SCLC who had received treatment, 14 patients with benign lung diseases and 12 normal subjects. Its relationship with tumor stage and therapeutic effects was observed. Result： The serum level of ProGRP31 -98 was significantly increased in patients with SCLC as compared to that of the normal controls as well as that in any other groups of patients. The diagnostic sensitivity and specificity of ProGRP to SCLC were 76% and 95% respectively. In chemotherapy sensitive cases, the ProGRP level had a significant decrease after treatment. Condusion： ProGRP as a new SCLC tumor marker with high specificity and sensitivity. It can be used as a predictor of SCLC to chemotherapy response.

关 键 词：小细胞肺癌 胃泌素释放肽前体 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]